Trial Profile
A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms VANILLA
- Sponsors Sanofi
- 05 Oct 2021 This trial has been completed in Spain and France (End Date: 28 Oct 2009), according to European Clinical Trials Database record.
- 05 Jun 2018 Results of prognostic nomogram using training and validation cohorts from (NCT00844649, NCT01124786 and NCT00574275) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2018 Results of pool data from the comparator arm of three clinical trails (NCT00844649, NCT01124786 and NCT00574275) in MPC treated with gemcitabine as first-line chemotherapy, were presented at the 2018 Gastrointestinal Cancers Symposium.